This program aims to develop anti-HCK therapeutic monoclonal antibody in the immuno-oncology.
Rationale of the program:
In summary, HCK directly inhibits cancer cells growth, or indirectly inhibits the tumor transformation in the tumor microenvironment, highlighting a rationale for HCK-based cancer immunotherapy.
Hematopoietic cell kinase (HCK) is a cytoplasmic non-receptor tyrosine kinases (SFK) belongs to the SRC cytoplasmic family. HCK is mainly expressed in the bone marrow and B lymphocyte cell lineages and has nine distinct subsets: Blk, c-Src, Fyn, Fgr, Hck, Lck, Lyn, Yes and Yrk. The SFK family has proven to be a potential therapeutic target, as reflected in their roles:
Fig.1 Simplified schematic depiction of HCK signaling in cancer cells.1
Here are some published data about HCK working as a potential target for cancer immunotherapy.
Fig.2 Activated FGR and HCK associate with poor prognosis in patients undergoing potentially curative resection of colorectal cancer.2
Fig.3 Src family inhibitor enhanced SS1P toxicity in mouse xenograft model.3
We have extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.
Fig.4 Project pipeline management of therapeutic monoclonal antibody.
Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop anti-HCK therapeutic monoclonal antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership. For any partners interest in our Next-IO™ programs, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.
With our quality control protocol and knowledge of global regulatory requirements, we can help our partners advance their programs with more chance to succeed. Look forward to cooperating with you in the near future.
For Research Use Only | Not For Clinical Use